Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Return on Capital Employed (2017 - 2026)

Ovid Therapeutics filings provide 10 years of Return on Capital Employed readings, the most recent being 27.67% for Q1 2026.

  • Quarterly Return on Capital Employed rose 4580.0% to 27.67% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 27.67% through Mar 2026, up 4580.0% year-over-year, with the annual reading at 37.47% for FY2025, 2006.0% up from the prior year.
  • Return on Capital Employed hit 27.67% in Q1 2026 for Ovid Therapeutics, up from 42.82% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 27.67% in Q1 2026 and bottomed at 73.47% in Q1 2025.
  • Average Return on Capital Employed over 5 years is 51.83%, with a median of 48.06% recorded in 2023.
  • The largest annual shift saw Return on Capital Employed crashed -10304bps in 2022 before it surged 4580bps in 2026.
  • Ovid Therapeutics' Return on Capital Employed stood at 36.27% in 2022, then tumbled by -33bps to 48.17% in 2023, then tumbled by -48bps to 71.22% in 2024, then soared by 40bps to 42.82% in 2025, then soared by 35bps to 27.67% in 2026.
  • Per Business Quant, the three most recent readings for OVID's Return on Capital Employed are 27.67% (Q1 2026), 42.82% (Q4 2025), and 64.01% (Q3 2025).